Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Torray Investment Partners LLC

Torray Investment Partners LLC lowered its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 20.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 684,007 shares of the biopharmaceutical company’s stock after selling 173,912 shares during the period. Royalty Pharma makes up about 2.5% of Torray Investment Partners LLC’s holdings, making the stock its 9th biggest position. Torray Investment Partners LLC’s holdings in Royalty Pharma were worth $17,449,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Keene & Associates Inc. grew its stake in Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 370 shares during the period. Blue Trust Inc. grew its stake in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the period. Sanctuary Advisors LLC grew its stake in Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $1,068,000 after purchasing an additional 388 shares during the period. Aurora Investment Counsel grew its stake in Royalty Pharma by 1.0% during the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock worth $1,427,000 after purchasing an additional 512 shares during the period. Finally, GAMMA Investing LLC grew its stake in Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 590 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Stock Up 0.7 %

RPRX stock opened at $33.86 on Tuesday. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average is $30.23 and its 200-day moving average is $28.24. The firm has a market capitalization of $19.52 billion, a PE ratio of 23.35, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Sell-side analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.